Blocking Tyr265 nitration of protein phosphatase 2A attenuates nitrosative stress–induced endothelial dysfunction in renal microvessels

Abstract

Protein tyrosine (Tyr) nitration, the covalent addition of a nitro group (•NO2) to Tyr residues, is emerging as a candidate mechanism of endothelial dysfunction. Previous studies have shown that Tyr nitration is primarily induced by nitrosative stress, a process characterized by the production of reactive nitrogen species, especially peroxynitrite anion (ONOO−), which is considered a secondary product of NO in the presence of superoxide radicals (O2•−). However, the impact of nitrosative stress–induced Tyr nitration on endothelial dysfunction has not been thoroughly elucidated to date. We developed an endothelial dysfunction model, a process called “endothelial‐to‐mesenchymal transition (EndMT),” and evaluated the production of NO, O2•−, and protein nitration during EndMT. The results showed that TGF‐β1 stimulation induced EndMT and elevated endothelial NO and O2•− production as well as nitration of the catalytic subunit of protein phosphatase (PP)2A. Mass spectrometry analysis showed that Tyr265 was the nitration site in the catalytic subunit of protein phosphatase (PP)2A, and this Tyr nitration increased PP2A activity and disrupted endothelial integrity. To devise an endothelial‐targeted anti‐PP2Ac nitration strategy, a mimic peptide, tyrosine 265 wild type (Y265WT), conjugated with the cell‐penetrating peptide HIV‐1 TAT protein (TAT) was synthesized. PP2Ac nitration and PP2A activity were significantly inhibited by pretreatment with TAT‐265WT, and the integrity of endothelial cells was maintained. Furthermore, injection of TAT‐265WT attenuated renal nitration formation and caused anticapillary rarefaction in a unilateral urethral obstructive nephropathy model. Taken together, these results offer preclinical proof of concept for TAT‐265WT as a tractable agent to protect against nitrosative stress‐induced endothelial dysfunction in renal microvessels.—Deng, Y., Cai, Y., Liu, L., Lin, X., Lu, P., Guo, Y., Han, M., Xu, G. Blocking Tyr265 nitration of protein phosphatase 2A attenuates nitrosative stress–induced endothelial dysfunction in renal microvessels. FASEB J. 33, 3718–3730 (2019). http://www.fasebj.org

Anti‐renal interstitial fibrosis effect of norcantharidin is exerted through inhibition of PP2Ac‐mediated C‐terminal phosphorylation of Smad3

“…The PP2A subunit PP2Ac is known to regulate a variety of cellular processes including signal transduction, cell differentiation, and apoptosis (Seshacharyulu, Pandey, Datta, & Batra, 2013). A large body of evidence suggests that dysregulation of PP2Ac has been implicated in pathologic processes such as hepatocyte apoptosis and endothelial dysfunction (Deng et al., 2019; Sunahori et al., 2013; Xiong et al., 2019). We previously demonstrated using in vivo and in vitro fibrosis models that PP2Ac overexpression promoted RIF; additionally, we showed that the anti‐RIF effect of NCTD was associated with the downregulation of PP2Ac in HK‐2 cells (Hou, 2015).…”

Ginsenoside Rg1 ameliorates chronic intermittent hypoxia-induced vascular endothelial dysfunction by suppressing the formation of mitochondrial reactive oxygen species through the calpain-1 pathway

“…PP2A is a complex heterotrimeric serine/threonine phosphatase that implicates in many cellular processes, including mitochondrial dysfunction and apoptosis [ [36] , [37] , [38] ]. Studies have shown that blocking the expression of PP2A attenuates high glucose-induced ROS accumulation and inflammation [ 30 ].…”

High fructose induces dysfunctional vasodilatation via PP2A-mediated eNOS Ser1177 dephosphorylation

“…PP2A could separate the phosphate groups from the substrate by hydrolysing the phosphate bond, and dephosphorylating serine/threonine phosphate [53]. PP2A can affect the phosphorylation degree of many proteins in endothelial cells, such as occludin [54] and flotillin-1 (Ser315) [55]. eNOS is also one of the specific substrates for PP2A, and PP2A causes dephosphorylation of eNOS at Ser 1177 [56].…”